Can Oral Bisphosphonate Cut Post-Implant Revision Sx Risk?
(HealthDay News) — For patients undergoing total joint replacement, oral bisphosphonate use is associated with a reduction in the risk of revision surgery, according to a study published in the November issue of Arthritis & Rheumatology.
Daniel Prieto-Alhambra, MD, PhD, from the University of Oxford in the United Kingdom, and colleagues conducted a retrospective cohort study within Danish nationwide registries to examine the correlation between bisphosphonate use and implant survival. Patients aged ≥40 years undergoing total joint replacement between 1998–2007 were identified. Each of 1,558 bisphosphonate users was matched, using propensity scores, to up to six bisphosphonate nonusers (n=8,966).
The researchers found that during the follow-up period, 1.73% of bisphosphonate users and 4.45% of matched nonusers underwent revision surgery, at a median of 2.61 years after first surgery. Bisphosphonate users had a reduced risk of revision surgery (hazard ratio, 0.41). Patients with the longest duration of treatment and/or the best adherence had the strongest correlation.
"Oral bisphosphonate users have a 59% reduced risk of revision surgery," the authors write. "This association is only present when bisphosphonates are started after arthroplasty surgery."
Several authors disclosed financial ties to the pharmaceutical industry.